# Vebreltinib for Advanced or Metastatic CCS

> **NCT07153887** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Clear Cell Sarcoma (CCS)

## Interventions

- **DRUG:** Vebreltinib
- **OTHER:** Standard medical treatment

## Key facts

- **NCT ID:** NCT07153887
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2026-07-15
- **Final completion:** 2027-07-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07153887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07153887, "Vebreltinib for Advanced or Metastatic CCS". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07153887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*